Optimal management of amiodarone therapy: Efficacy and side effects

Pharmacotherapy

Volumn 18, Issue 6 II, 1998, Pages

  Hilleman, Daniel ^a   Miller, Mary Ann ^a   Parker, Robert ^a   Doering, Paul ^a   Pieper, John A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; DIGOXIN; MEXILETINE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; WARFARIN;

ALLERGIC PNEUMONITIS; CLINICAL FEATURE; CONFERENCE PAPER; DOSE CALCULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG POTENTIATION; HEART ARRHYTHMIA; HUMAN; INTERSTITIAL PNEUMONIA; LIVER FUNCTION TEST; LUNG TOXICITY; NEUROTOXICITY; OPTIC NERVE DISEASE; SKIN TOXICITY; THYROID DISEASE; TORSADE DES POINTES;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; HUMANS;

EID: 0031784747     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (59)

1. Podrid PJ. Amiodarone: reevaluation of an old drug. Ann Intern Med 1995;122:689-700.
2. Jafari-Fesharaki M, Scheinman MM. Adverse effects of amiodarone. Pacing Clin Electrophysiol 1998;21(1 Pt 1):108-20.
3. Pichler WJ, Schindler L, Staubli M, Stadler BM, de Weck AL. Anti-amiodarone antibodies: detection and relationship to the development of side effects. Am J Med 1988;85:197-202.
4. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomized trials. Lancet 1997;350:1417-24.
5. Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low-dose amiodarone: a meta-analysis. J Am Col Cardiol 1997;30:791-8.
6. Magro SA, Hirschhorn SG, Lawrence C, et al. High frequency of amiodarone pulmonary toxicity: role of diffusion capacity [abstr]. Circulation 1985;72(suppl II):272.
7. Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1990;16:1711-18.
8. Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, et al. Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. J Am Coll Cardiol 1992;20:1056-62.
9. Navarro-Lopez F, Cosin J, Marrugat J, et al. Comparison of the effects of amiodarone versus metoprolol on the frequency of ventricular arrhythmias and on mortality after acute myocardial infarction. Spanish study on sudden death. Am J Cardiol 1993;72:1243-8.
10. The CASCADE Investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study). Am J Cardiol 1993;72:280-7.
11. Marchlinski FE, Gansler TS, Waxman HL, Josephson ME. Amiodarone pulmonary toxicity. Ann Intern Med 1982;97:839-45.
12. Magro SA, Lawrence EC, Wheeler SH, Krafchek J, Lin HT, Wyndham CR. Amiodarone pulmonary toxicity: prospective evaluation of serial pulmonary function tests. J Am Coll Cardiol 1988;12:781-8.
13. Dusman RE, Stanton MS, Miles WM, et al. Clinical features of amiodarone-induced pulmonary toxicity. Circulation 1990;82:51-9.
14. Martin WJ 2d, Rosenow EC 3d. Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part 2). Chest 1988;93P:1242-8.
15. Martin WJ 2d, Rosenow EC 3d. Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part 1). Chest 1988;93:1067-75.
16. Fraire A, Guntupalli K, Greenberg D, Cartwright J, Chasen M. Amiodarone pulmonary toxicity: a multidisciplinary review of current studies. South Med J 1993;86:67-76.
17. Heger JJ, Prystowsky EN, Miles WM, et al. Clinical use and pharmacology of amiodarone. Med Clin North Am 1984;68:1339-66.
18. Vrobel T, Miller P, Mostow N, Rakita L. A general overview of amiodarone toxicity: its prevention, detection and management. Prog Cardiovasc Dis 1989;31:393-426.
19. Harris L, McKenna WJ, Rowland E, Krikler DM. Side effects and possible contraindications of amiodarone use. Am Heart J 1983;106(4 Pt 2):916-23.
20. Harris L, McKenna WJ, Rowland E, Holt D, Storey G, Krikler D. Side effects of long-term amiodarone therapy. Circulation 1983;67:45-51.
21. Nygaard TW, Sellers TD, Cook TS, DiMarco JP. Adverse reactions to antiarrhythmic drugs during therapy for ventricular arrhythmias. JAMA 1986;256:55-7.
22. Rotmensch HH, Belhassen B, Swanson BN, et al. Steady-state serum amiodarone concentrations: relationships with antiarrhythmic efficacy and toxicity. Ann Intern Med 1984;101:462-9.
23. Santinelli V, Chiariello M, Santinelli C, Condorelli M. Ventricular tachyarrhythmias complicating amiodarone therapy in the presence of hypokalemia. Am J Cardiol 1984;53:1462-3.
24. Cairns JA, Connolly SJ, Roberts RS, et al. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations: CAMIAT. Lancet 1997;349:675-82.
25. Brown MA, Smith WM, Lubbe WF, Norris RM. Amiodarone-induced torsades de pointes. Eur Heart J 1986;7:234-9.
26. Sclarovsky S, Lewin RF, Kracoff O, Strasberg B, Arditti A, Agmon J. Amiodarone-induced polymorphous ventricular tachycardia. Am Heart J 1983;105(1):6-12.
27. Holnloser S, Klinggenheben T, Singh B. Amiodarone-associated proarrhythmic effects: a review with special reference to torsade de pointes tachycardia. Ann Intern Med 1994;121:529-35.
28. Mattioni TA, Zheutlin TA, Sarimento JJ, et al. Amiodarone in patients with previous drug-mediated torsade de pointes. Long-term safety and efficacy. Ann Intern Med. 1989;111:574-80.
29. Morady F, Scheinman MM, Shen E, Shapiro W, Sung RJ, DiCarlo L. Intravenous amiodarone in the acute treatment of recurrent symptomatic ventricular tachycardia. Am J Cardiol 1983;51:156-9.
30. Fogoros RN. Amiodarone-induced refractoriness to cardioversion. Ann Intern Med 1984;100:699-700.
31. Raeder EA, Podrid PJ, Lown B. Side effects and complications of amiodarone therapy. Am Heart J 1985;109(5 Pt 1):975-83.
32. Nademanee K, Piwonka RW, Singh BN, Hershman JM. Amiodarone and thyroid function. Prog Cardiovasc Dis 1989;31:427-37.
33. Nademanee K, Singh BN, Callahan B, Hendrickson JA, Hershman JM. Amiodarone, thyroid hormone indexes, and altered thyroid function: long-term serial effects in patients with cardiac arrhythmias. Am J Cardiol 1986;58:981-6.
34. Smyrk TC, Goellner JR, Brennan MD, Carney JA. Pathology of the thyroid in amiodarone-associated thyrotoxicosis. Am J Surg Pathol 1987;11:197-204.
35. Newman CM, Price A, Davies DW, Gray TA, Weetman AP. Amiodarone and the thyroid: a practical guide to the management of thyroid dysfunction induced by amiodarone therapy. Heart 1998;79:121-7.
36. Ingram DV. Ocular effects in long-term amiodarone therapy. Am Heart J 1983;106(4 Pt 2):902-5.
37. Mantyjarvi M, Tuppurainen K, Ikaheimo K. Ocular side effects of amiodarone. Surv Ophthalmol 1998;42:360-6.
38. Wyeth-Ayerst Laboratories. Cordarone (amiodarone HCl) package insert. Philadelphia, PA; 1998.
39. McEvoy G, Litvak K, Welsh OH, eds. AHFS 97 drug information. Bethesda, MD: American Society of Health-System Pharmacists, 1997.
40. Zipes DP, Prystowsky EN, Heger JJ. Amiodarone: electrophysiologic actions, pharmacokinetics, and clinical effects. J Am Coll Cardiol 1984;3:1059-71.
41. Adams PC, Holt DW, Storey GC, Morley AR, Callaghan J, Campbell RW. Amiodarone and its desethyl metabolite: tissue distribution and morphologic changes during long-term therapy. Circulation 1985;72:1064-75.
42. Wilson JS, Podrid PJ. Side effects from amiodarone. Am Mean J 1991;121(1 Pt 1):158-71.
43. Rees A, Dalal JJ, Reid PG, et al. Dangers of amiodarone and anticoagulant treatment. Br Med J 1981;282:1756-7.
44. Serlin MJ, Sibeon RG, Green GJ. Dangers of amiodarone and anticoagulant treatment. Br Med J 1981;283:58.
45. Martinowitz U, Rabinovici J, Goldfarb D, et al. Interaction between warfarin sodium and amiodarone. N Engl J Med 1981;304:671-2.
46. Hamer A, Peter T, Mandel WJ, et al. The potentiation of warfarin anticoagulation by amiodarone. Circulation 1982;65:1025-9.
47. Moysey JO, Jaggarao NSV, Grundy EN, et al. Amiodarone increases plasma digoxin concentration. Br Med J 1981; 282:272.
48. Oetgen WJ, Sobol SM, Tri TB, et al. Amiodarone-digoxin interaction. Clinical and experimental observations. Chest 1984;86:75-9.
49. Nademanee K, Kannan R, Hendrickson J, et al. Amiodarone-digoxin interaction: clinical significance, time course of development, potential pharmacokinetic mechanisms, and therapeutic implications. J Am Coll Cardiol 1984;4:111-16.
50. Fenster PE, White NW, Hanson CD. Pharmacokinetic evaluation of the digoxin-amiodarone interaction. J Am Coll Cardiol 1985;5:108-12.
51. Tartini R, Kappenberger L, Steinbrunn W, et al. Dangerous interaction between amiodarone and quinidine. Lancet 1982;1:1327-9.
52. Saal AK, Werner JA, Greene HL, et al. Effect of amiodarone on serum quinidine and procainamide levels. Am J Cardiol 1984;53:1264-7.
53. Singh BN. Amiodarone: historical development and pharmacologic profile. Am Heart J 1983;106:788-97.
54. Kerin NZ, Aragon E, Faitel K, Frumin H, Rubenfire M. Long-term efficacy and toxicity of high- and low-dose amiodarone regimens. J Clin Pharmacol 1989;29:418-23.
55. Kowey PR, Friehling TD, Marinchak RA, Sulpizi AM, Stohler JL. Safety and efficacy of amiodarone. The low-dose perspective. Chest 1988;93:54-9.
56. Collaborative Group for Amiodarone Evaluation. Multicenter controlled observation of a low-dose regimen of amiodarone for treatment of severe ventricular arrhythmias. Am J Cardiol 1984;53:1564-9.
57. Phillips BG, Bauman JL. Prescribing trends and pharmacoeconomic considerations in the treatment of arrhythmias. Focus on atrial fibrillation and flutter. Pharmacoeconomics 1995;7:521-33.
58. Podrid PJ. Practical follow-up guidelines for patients treated with amiodarone. Clin Cardiol 1987;10(7 suppl 1):110-16.
59. Howard PA. Amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. Ann Pharmacother 1995;29:596-602.